Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
Chuikyo Rep Interview 2-3 - With 80% Generic Share, Now Is the Time to Revisit LLP Copay, Says Payer Rep
As debates for the FY2024 drug pricing reform get into full swing, this occasional interview series aims to illuminate the views of members of the Central Social Insurance Medical Council (Chuikyo). The National Federation of Health Insurance Societies (Kenporen) was…
To read the full story
Related Article
- Chuikyo Rep Interview 4 - JMA Rep Says Any Reform Must Ensure Access to Appropriate Healthcare
November 6, 2023
- Chuikyo Rep Interview 3-2 - Rengo Wants Substantive Discussions on Pricing System, Off-Year Revisions over Next Few Years
October 26, 2023
- Chuikyo Rep Interview 3-1 - Rengo Seeks Patient-Centric Debate, Sees Exhausted Wholesalers as Big Issue
October 25, 2023
- Chuikyo Rep Interview 2-2 - Payer Says Drug Prices Not Only Cause of Lag/Loss, Industry Proposal Needs More Details
October 11, 2023
- Chuikyo Rep Interview 2-1 - As Japan Sees More Pricey Meds, Kenporen Director Wants Rethink of Health Coverage
October 10, 2023
- Chuikyo Rep Interview 1 - JPA Vice President Warns against Rushed Dabate on Yakkasa, 2% Buffer Zone
October 4, 2023
ORGANIZATION
- Pharma Group Looks to Growth Strategy under Takaichi after Election Win
February 10, 2026
- Pharma Groups Call for Faster Diagnosis and R&D for Intractable, Rare Diseases
February 9, 2026
- Generic Industry Consolidation Opens Opportunities for CMOs: Industry Chief
February 6, 2026
- FIRM Warns Conditional Approval Pricing Change Could Chill Regenerative Medicine R&D
February 3, 2026
- AMDD to Continue Policy Advocacy to Address Device Lag and Loss: Chair
January 28, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…